BioCentury | Jun 5, 2019
Finance
EpimAb raises $74M series B round to accelerate bispecific immuno-oncology pipeline expansion
...participated, along with existing investors Oriza Seed Venture Capital, Decheng Capital, 3E Bioventures Capital and Trend Investment Group...
